Fact-checked by Grok 2 weeks ago

Window period

The window period is the time interval between initial exposure to an infectious pathogen and the point at which a diagnostic test can reliably detect markers of infection, such as antibodies or antigens, due to the time required for the body's immune response or pathogen replication to reach detectable levels.^[1] This period varies significantly depending on the pathogen, the type of test used, and individual factors like immune status, making it a critical concept in infectious disease diagnosis and prevention.^[2] The window period poses challenges in clinical settings, as individuals may be infectious and capable of transmitting the disease during this undetected phase, particularly in contexts like blood donation, sexual health screening, and outbreak control.^[3] It informs guidelines for retesting after potential exposure, with negative results during the window period not ruling out infection, and has driven advancements in testing technologies, such as nucleic acid amplification tests (NAT), to shorten these intervals and reduce transmission risks.^[4] For instance, in transfusion medicine, understanding window periods helps estimate the residual risk of transmitting infections like HIV or hepatitis from screened donors.^[2] Window periods differ across major pathogens and assays; for HIV, NAT detects infection in 10–33 days post-exposure, while antibody tests may take 23–90 days.^[4] In hepatitis C virus (HCV) infection, viral RNA via NAT becomes detectable within 1–2 weeks, but antibody tests can have a window of up to 6 months, necessitating RNA testing for recent exposures.^[5] For hepatitis B virus (HBV), NAT has reduced the window period to approximately 20–30 days from longer serological intervals, minimizing risks in blood supply screening.^[6] Syphilis testing shows shorter windows, with treponemal tests detecting infection within 2 weeks of primary exposure, though nontreponemal assays may lag slightly in early stages.^[7] These variations underscore the need for pathogen-specific testing strategies to ensure timely diagnosis and intervention.^[8]

Definition and Key Concepts

Definition of Window Period

The window period refers to the interval following initial infection with a pathogen, such as a virus or bacterium, during which diagnostic tests cannot reliably detect the infection due to insufficient levels of biomarkers like antibodies, antigens, or nucleic acids.^[1] During this phase, the pathogen actively replicates within the host, but the concentrations of these markers remain below the detection threshold of available assays, potentially allowing transmission despite the absence of a positive test result.^[8] The concept of the window period emerged in the 1980s amid efforts to enhance blood transfusion safety, as the HIV/AIDS epidemic and cases of hepatitis transmission via contaminated blood underscored the limitations of early serological screening methods in identifying recently infected donors.^[9] In general, the window period lasts from a few days to several months, depending on the pathogen and the diagnostic technology used.^[10] For antibody-based tests, this interval concludes with seroconversion, when antibody levels become detectable.^[11]

Relation to Seroconversion and Incubation Period

Seroconversion refers to the biological process in which an infected individual develops detectable levels of specific antibodies (or sometimes antigens) in the blood, indicating the maturation of the adaptive immune response against the pathogen. This event typically occurs weeks after initial infection and represents a critical transition in the host's immune dynamics.^[12] The window period directly interfaces with seroconversion as its endpoint for antibody-based diagnostic assays, concluding when these antibodies reach thresholds sufficient for detection. In contrast, for nucleic acid amplification tests (NAAT), which target pathogen genetic material, the window period may terminate earlier, enabling identification before serological markers emerge. This distinction underscores how test modality influences the temporal boundary of undetectability.^[4]^[12] Unlike the window period, which pertains exclusively to diagnostic detectability, the incubation period denotes the interval from pathogen acquisition to the appearance of clinical symptoms, reflecting the time required for sufficient pathogen replication and tissue damage to manifest signs of illness. These phases may temporally overlap, as symptom onset can occur while serological tests remain negative, but they are not equivalent. In some infectious diseases, the window period extends into or beyond the incubation period, especially if symptoms arise prior to seroconversion in antibody-dependent testing scenarios.^[13]

Clinical and Diagnostic Importance

Challenges in Early Detection

One of the primary challenges in early detection during the window period is the high risk of false-negative results, where diagnostic tests fail to identify an active infection because detectable markers, such as antibodies or antigens, have not yet developed to sufficient levels.^[14] This limitation can lead to an underestimation of infection prevalence, as individuals who test negative may actually be infectious and capable of transmitting the pathogen unknowingly.^[15] The impact on affected individuals is profound, as undetected infections during this phase allow the disease to progress unchecked, potentially advancing to more severe stages before diagnosis and treatment can begin.^[16] Moreover, this period facilitates unwitting transmission through close contacts, such as sexual partners or shared needles, exacerbating community spread without awareness of the risk.^[17] In contexts like blood donation, historical instances of transfusion-transmitted infections have underscored these dangers, with early screening methods unable to detect pathogens within the window period, prompting the adoption of nucleic acid amplification tests (NAAT) to shorten detection times and enhance blood supply safety.^[18] To mitigate these risks, clinical guidelines recommend repeat testing protocols following potential exposure, typically at intervals such as 6 weeks and 3 months, to capture seroconversion that may occur after the initial window period.^[4] These follow-up assessments account for variability in immune response timing and help confirm negative results over time. Ethical considerations further complicate early detection efforts, particularly around informed consent, where healthcare providers must clearly communicate the possibility of false negatives due to the window period to ensure patients understand testing limitations and the need for retesting.^[19] This transparency is essential to uphold patient autonomy and prevent misconceptions that could influence health decisions or behaviors.^[20]

Implications for Testing and Public Health

The window period has driven significant advancements in HIV testing algorithms, evolving from early antibody-only assays, which had detection windows of up to 90 days, to fourth-generation antigen/antibody combination tests that reduce the window to 18-45 days by detecting both p24 antigen and antibodies.^[4] Further integration of nucleic acid amplification tests (NAAT) in confirmatory steps has shortened the effective window to as little as 10-33 days post-exposure, as reflected in updated CDC guidelines recommending laboratory-based antigen/antibody screening followed by NAAT for reactive results to enhance early detection, including the 2023 technical update on HIV NATs for diagnostics.^[21] ^[22] These shifts, formalized in protocols like the 2014 CDC/APHL algorithm with subsequent clarifications, prioritize reducing diagnostic delays to facilitate timely intervention.^[23] In public health, awareness of the window period has underpinned mandatory screening in high-risk contexts, such as blood banks, where post-1985 implementation of HIV antibody testing and subsequent adoption of p24 antigen screening in 1996, followed by NAAT in 1999, drastically lowered transfusion-related transmissions from thousands annually in the early 1980s to near zero by the 2000s.^[24] These policies, informed by the window period's risks during the eclipse phase of infection, have informed broader screening mandates, including routine opt-out testing in healthcare settings, contributing to a 20-30% reduction in undiagnosed HIV cases over decades through iterative improvements.^[25] To address gaps posed by the window period, public health strategies emphasize pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) for HIV, which provide preventive coverage during potential exposure periods before detectable infection, with CDC guidelines recommending PEP initiation within 72 hours of exposure to avert seroconversion.^[26] PrEP, particularly daily oral tenofovir-emtricitabine, is promoted for ongoing high-risk individuals to mitigate acquisition risks that could otherwise fall within undetected windows, achieving up to 99% efficacy in adherence-adherent users and integrating with testing to monitor for breakthrough infections.^[27] In resource-limited settings, prolonged window periods due to reliance on less sensitive antibody tests exacerbate HIV epidemics by delaying diagnosis and treatment, leading to higher transmission rates; the World Health Organization (WHO) counters this by recommending point-of-care NAAT for early infant diagnosis to close detection gaps in high-burden areas.^[28] Such measures address global disparities, where NAAT implementation has reduced pediatric HIV mortality by enabling earlier ART initiation in low-income regions. Window periods complicate HIV incidence surveillance by under-detecting recent infections, necessitating epidemiological models that adjust for mean window durations—typically 25-45 days for antibody tests—to estimate true incidence from cross-sectional data, as outlined in UNAIDS-recommended methods using biomarkers like limiting-antigen avidity assays.^[29] These adjustments, incorporating window period variability, enable more accurate tracking of epidemic trends and resource allocation for prevention.^[11]

Factors Influencing the Window Period

Biological Factors

The length of the window period in infectious diseases is significantly influenced by pathogen-related factors, particularly the replication rate of the infectious agent. Viruses with rapid replication kinetics, such as HIV-1, exhibit an exponential increase in viral load shortly after infection, often doubling every 0.65 days during the acute phase, which allows for earlier detection via nucleic acid amplification tests (NAAT) targeting viral RNA.^[30] However, this fast replication can delay the onset of a detectable immune response, thereby prolonging the window for antibody-based assays as the host's adaptive immunity takes time to mount.^[31] Viral load dynamics further modulate the window period, with initial low viremia post-infection often rendering the pathogen undetectable by antigen or RNA tests until a critical threshold is reached. In HIV-1, plasma viral load typically peaks at around 10^8 copies per milliliter within the first few weeks, but early fluctuations due to innate immune containment can extend the undetectable phase.^[32] Viral genotypes also play a role; for instance, certain HIV-1 subtypes or group O variants replicate at differing rates or evade early detection more effectively due to antigenic differences, leading to variability in window duration across strains.^[31]^[33] Host immune factors are equally critical, as the efficiency of the immune response determines the timing of seroconversion—the development of detectable antibodies. In immunocompetent individuals, robust innate and adaptive responses facilitate faster antibody production, shortening the serological window period. Conversely, immunosuppression, such as from chemotherapy or concurrent infections, impairs B-cell function and delays seroconversion, potentially extending the window by weeks or more; case reports document seronegative HIV infections persisting until immune recovery in such scenarios.^[31]^[34] Genetic variations in the host, particularly human leukocyte antigen (HLA) alleles, influence antibody production timing by affecting antigen presentation and T-cell activation during early infection. Pathogen mutations can interact with these host genetics, further altering the pace of immune recognition and extending the window in mismatched scenarios.^[35]^[36] Age and overall health status also contribute to window period variability, with extremes of age often resulting in prolonged durations due to immature or declining immune competence. In infants, underdeveloped adaptive immunity and potential maternal antibody interference can delay reliable serological detection in diseases like HIV or hepatitis B, necessitating alternative virological tests. Similarly, elderly individuals or those with chronic comorbidities exhibit weakened humoral responses, leading to extended windows as antibody titers rise more slowly post-infection.^[31]^[37]

Technological and Testing Factors

The length of the window period is significantly influenced by the type of diagnostic test employed, with a clear hierarchy based on what the test detects. For example, in HIV, antibody tests, which identify immune responses to the pathogen, typically exhibit the longest window periods, ranging from 3 to 12 weeks, as they rely on the development of detectable antibodies following infection.^[38] Antigen tests, which detect viral proteins directly, shorten this interval to approximately 2 to 6 weeks by targeting earlier markers of infection.^[4] Nucleic acid amplification tests (NAAT), such as PCR, offer the shortest windows of 10 to 33 days through direct detection of pathogen RNA or DNA, enabling identification during the acute phase before serological markers appear.^[38] Advances in test sensitivity and specificity have progressively reduced window periods by improving early detection thresholds. For instance, fourth-generation combination tests for HIV, which simultaneously detect both antibodies and the p24 antigen, can identify infection a median of 18 days earlier than antibody-only assays, bridging the gap between viral replication and serological response.^[39] These improvements stem from enhanced assay designs that lower the limit of detection for antigens produced shortly after infection, thereby minimizing false negatives during the initial window.^[1] The choice of sample type also modulates the effective window period, as sensitivity varies with collection method. Blood plasma or serum samples generally yield higher sensitivity due to higher concentrations of biomarkers compared to oral fluid, which can extend the window by several weeks in non-invasive tests because antibodies accumulate more slowly in saliva.^[40] This difference is particularly relevant for screening programs prioritizing accessibility, where oral fluid tests may delay confirmation of early infections.^[1] Laboratory-based tests often achieve shorter window periods than point-of-care (POC) or rapid tests due to superior analytical performance. Rapid POC tests, while convenient, frequently have reduced sensitivity—detecting infection only 18 to 90 days post-exposure in finger-prick formats—leading to longer effective windows compared to lab venipuncture assays (18 to 45 days).^[4] This trade-off reflects the simplified reagents and instrumentation in POC devices, which prioritize speed over the precision of centralized laboratory methods.^[38] As of 2025, recent technological advancements, including multiplex PCR and RT-PCR assays, have further shortened window periods by enabling simultaneous detection of multiple pathogens with high sensitivity in under an hour, even in self-testing formats for HIV and related infections.^[41] These integrated platforms, such as those combining RNA extraction with multiplex amplification, reduce diagnostic delays across co-infections like HIV and hepatitis C, enhancing early intervention capabilities.^[42]

Examples in Infectious Diseases

HIV

The window period for HIV infection varies by testing method, reflecting the time required for detectable levels of viral components or immune responses to emerge after exposure. Nucleic acid amplification tests (NAAT), which detect HIV RNA, have a window period of 10-33 days. Fourth-generation antigen/antibody tests, which identify both p24 antigen and HIV antibodies, typically have a window of 18-45 days for laboratory-based assays using venous blood. Antibody-only tests, such as third-generation immunoassays, exhibit a longer window of 23-90 days. According to modeling from seroconversion panels, the median window period across modern assays is 18 days, meaning 50% of infections are detectable by this point.^[38]^[39] Viral dynamics during acute HIV infection influence the window period's endpoint, as the virus rapidly replicates following exposure, leading to peak viremia around 2-4 weeks. This phase often coincides with or follows the onset of acute retroviral syndrome (ARS), a flu-like illness occurring in 40-90% of cases approximately 2-4 weeks post-exposure, marked by symptoms such as fever, rash, and lymphadenopathy. ARS typically emerges toward the end of the window period for antigen/antibody tests, but NAAT can detect infection earlier during high viremia; however, about 50% of infections remain undetectable by day 18 with less sensitive assays.^[43]^[39] The Centers for Disease Control and Prevention (CDC) recommends HIV testing protocols post-exposure to account for these windows (as of 2025 guidelines), starting with a baseline antigen/antibody (Ag/Ab) test immediately after potential exposure, followed by Ag/Ab plus NAAT at 4-6 weeks, and final testing at 12 weeks post-exposure using laboratory-based Ag/Ab and NAAT assays. This timeline ensures detection in most cases; additional testing at baseline with NAAT may be needed for specific scenarios such as recent exposure to long-acting injectable PrEP. Historically, recognition of the HIV window period prompted the implementation of antibody screening for U.S. blood donations in March 1985, shortly after the first commercial test's licensure, dramatically reducing transfusion-transmitted infections from over 1,000 annual cases pre-screening to near elimination.^[44]^[45] In special populations, the window period may extend due to atypical immune responses. Elite controllers—rare individuals (less than 1% of those with HIV) who maintain undetectable viral loads without therapy—can experience prolonged seroconversion, with antibody detection delayed beyond standard windows in documented cases, complicating diagnosis via immunoassay. Similarly, PEP administration, if it fails to prevent infection, can suppress early viral replication and delay marker emergence, potentially extending the effective window by weeks and necessitating prolonged follow-up testing.^[46]^[40]

Viral Hepatitis

In viral hepatitis, the window period refers to the interval between infection and detectable serological or molecular markers, which varies significantly between hepatitis B virus (HBV) and hepatitis C virus (HCV) due to differences in viral replication and host immune responses. For HBV, a DNA virus of the Hepadnaviridae family, surface antibodies (anti-HBs) typically become detectable 6 weeks to 6 months after exposure in resolving acute infections, marking the transition to immunity. Core antibodies (anti-HBc) emerge earlier, usually within 1-9 weeks post-exposure, serving as an indicator of prior or ongoing infection during the serologic window when hepatitis B surface antigen (HBsAg) has cleared but anti-HBs is not yet present. Nucleic acid amplification tests (NAAT) for HBV DNA can detect viremia as early as 2-6 weeks after infection, shortening the diagnostic window compared to serology alone. For HCV, an RNA virus of the Flaviviridae family, antibody detection occurs later, with a window period of 2-26 weeks post-exposure, reflecting the time required for seroconversion. In contrast, NAAT detects HCV RNA within 1-2 weeks due to rapid onset of viremia, often before symptoms or antibodies appear. HCV's propensity for chronicity—progressing to persistent infection in approximately 75-85% of cases—prolongs the relevance of the window period for ongoing transmission risks, whereas HBV resolves acutely in about 90% of immunocompetent adults, effectively limiting the window's impact in most cases. These differences underscore HBV's potential for self-resolution versus HCV's frequent chronic course, influencing detection strategies; for instance, HBV's acute clearance in 90% of adult cases shortens the effective diagnostic window, while HCV's chronicity heightens the importance of early NAAT for blood screening to prevent onward spread. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend NAAT alongside serologic testing for early detection in high-risk groups, such as injection drug users and healthcare workers. As of 2025, CDC guidelines recommend universal one-time screening using triple-panel serology (HBsAg, anti-HBs, total anti-HBc) for HBV and anti-HCV antibody testing for HCV in adults aged 18 and older, with NAAT recommended alongside serology for early detection in high-risk groups or recent exposures, to streamline screening in at-risk populations and reduce diagnostic delays. The window periods exacerbate transmission risks in perinatal and transfusion settings. For HBV, maternal viremia during the early window can lead to perinatal transmission rates of up to 90% without intervention, necessitating immediate post-exposure prophylaxis for infants. Similarly, for HCV, the brief viremic window prior to antibody detection heightens transfusion risks, though universal NAAT screening has reduced this to near zero in screened blood supplies. Advances in test sensitivity, such as multiplex NAAT assays, have compressed the HCV antibody window from months to weeks, enhancing early intervention.

Syphilis and Other Examples

The window period for syphilis, caused by Treponema pallidum, varies by testing method and disease stage, reflecting the time from infection to detectable antibodies or direct pathogen identification. Non-treponemal tests, such as the rapid plasma reagin (RPR) or Venereal Disease Research Laboratory (VDRL) assay, typically become positive 21 days to 6 weeks after exposure, though sensitivity in early primary syphilis can be as low as 48.7%–92.7% compared to direct detection methods.^[47]^[7] Treponemal tests, including the Treponema pallidum particle agglutination (TPPA) or fluorescent treponemal antibody absorption (FTA-Abs), detect antibodies earlier, often in the third week for FTA-Abs and the fourth to fifth week for TPHA equivalents like TPPA, with sensitivities reaching 86.2%–100% in primary syphilis.^[47]^[7] Dark-field microscopy allows immediate detection of spirochetes from chancre fluid but is limited to active lesions and requires specialized expertise.^[47] The primary chancre, appearing after an incubation period of 10–90 days (average 21 days), often precedes serologic positivity, creating a diagnostic lag where approximately 20–40% of primary syphilis cases, particularly early ones, may test negative on nontreponemal assays.^[48]^[49] Reverse-sequence algorithms, starting with treponemal immunoassays followed by nontreponemal confirmation, can shorten the effective window by identifying infections sooner, though discordant results necessitate additional treponemal testing like TPPA for resolution.^[7] In pregnancy, the 2024 CDC and ACOG guidelines emphasize universal screening at the first prenatal visit, third trimester (ideally 28–32 weeks), and delivery to mitigate congenital risks, as the 10–21 day average incubation can lead to undetected early infections, contributing to preventable cases (88% of 2022 congenital syphilis incidents linked to screening gaps).^[50]^[7] Other bacterial sexually transmitted infections, such as gonorrhea (Neisseria gonorrhoeae) and chlamydia (Chlamydia trachomatis), exhibit shorter window periods due to rapid bacterial replication and antigen accumulation, contrasting with viral pathogens' reliance on slower immune responses. Nucleic acid amplification tests (NAATs) for these detect infection reliably after 1 week in most cases and 2 weeks in nearly all, enabling early diagnosis before symptoms, which may appear in 2–8 days for gonorrhea or 1–3 weeks for chlamydia.^[51] Reinfection can complicate interpretation, as prior exposure may not alter the short window but requires retesting.^[52] For herpes simplex virus (HSV), primarily HSV-2 in genital cases, polymerase chain reaction (PCR) testing from lesions detects viral DNA during outbreaks, with a window of 2–12 days from exposure to symptom onset (average 4 days), though optimal sensitivity occurs within 48 hours of lesion appearance to avoid false negatives as viral shedding declines.^[51]^[53] Variability arises from recurrent outbreaks, where detection depends on timing relative to symptoms rather than a fixed serologic lag.^[54]

References

[1]
Selecting an HIV Test: A Narrative Review for Clinicians and ... - NIH
The time from infection to the first reactive result on a given test is referred to as the window period, the length of which depends on the target being ...
[2]
Screening for transfusion-transmissible infections - NCBI - NIH
The various markers of infection appear at different times after infection. Each TTI has one or more window periods, ranging from a few days to months, ...
[3]
“Lookback” for Hepatitis C Virus (HCV): Product Quarantine ... - FDA
Apr 22, 2024 · ... screening test, but the infectious agent is present in the donor's blood (the “window period”). For example, if an individual donates blood ...
[4]
Getting Tested for HIV - CDC
Window period. No HIV test can detect HIV immediately after infection. That's because of the window period—the time between HIV exposure and when a test can ...<|control11|><|separator|>
[5]
Testing for Hepatitis C - CDC
Jan 31, 2025 · If you might have been exposed to HCV within the past 6 months, your doctor should order a NAT for HCV RNA rather than an HCV antibody test.Who Should Be Tested · Testing Methods · Testing Results
[6]
Infectious Disease Testing | Red Cross Blood Services
NAT has reduced the window-period from HBV infection to detection by about 12 days. This leaves an approximate period of 2 to 3 weeks when an infected donor ...
[7]
CDC Laboratory Recommendations for Syphilis Testing, United ...
Feb 8, 2024 · This report provides new CDC recommendations for tests that can support a diagnosis of syphilis, including serologic testing and methods for the identification ...<|control11|><|separator|>
[8]
Risk of Window Period HIV Infection in High Infectious Risk Donors
All serologic tests have a window period (WP), the time between acquisition of infection and serologic detectability (3). Infections acquired in the weeks to ...
[9]
Transfusion-Transmitted Infections: an Update on Product Screening ...
Jun 25, 2018 · The HIV/AIDS epidemic of the 1980s first demonstrated the vulnerability of the blood supply to emerging pathogens. Since then, the AABB ...
[10]
Estimates of risk of window-period transmission of blood-borne viral ...
We estimated the risk of transfusion-related transmission of viral disease attributable to the window period of laboratory testing (the period between infection ...
[11]
Estimating the distribution of the window period for recent HIV ... - NIH
It is clear that the window period is a fundamental ingredient in the estimation of HIV incidence. It depends on the rate of antibody response and hence can ...
[12]
The Role of Acute and Early HIV Infection in the Sexual ... - NIH
Seroconversion indicates a transition out of the acute phase and into the stage of early or recent infection in which antibodies are present and viral load ...<|separator|>
[13]
Glossary: Window Period - Blood Bank Guy
The window period is often confused with the incubation period (the time between exposure to an organism and development of symptoms).
[14]
A method to determine the duration of the eclipse phase for in vitro ...
May 21, 2015 · The time elapsed between successful cell infection and the start of virus production is called the eclipse phase. Its duration is specific ...
[15]
Window Period - an overview | ScienceDirect Topics
In individuals with possible recent exposure, antibody tests may be negative in the window period before seroconversion so testing should be repeated within 2–3 ...
[16]
False negative results on HIV tests - Aidsmap
Jun 8, 2024 · After the window period, in people who aren't taking antiretrovirals, false negative results are extremely rare. The accuracy of a single HIV ...
[17]
Window Periods: When to Get an STD Test for Accurate Results
Testing too early after exposure can lead to a false sense of security, as the infection may not be detectable yet. Delaying the test until the appropriate ...
[18]
Risks and challenges of HIV infection transmitted via blood transfusion
This time period, known as the “window period,” means that an individual who is infected may still initially test negative for the disease, risking the safety ...<|control11|><|separator|>
[19]
Transfusion-transmitted infections - Journal of Translational Medicine
Jun 6, 2007 · The implementation of viral NAT testing has greatly helped to reduce the residual risk of viral transmission during the 'window period' by ...Bacterial Infections · Transfusion-Transmitted... · West Nile Virus
[20]
Ethics in Consent for HIV Testing
I do not believe that changing the requirements for testing—from explicit consent to implied consent—will reduce the stigma of being seropositive.Missing: informed window
[21]
Testing and Informed Consent | The Center for HIV Law and Policy
The concept of informed consent, achieved through the process of physician-patient communication, is a legal and ethical obligation spelled out by statute and ...
[22]
Human Immunodeficiency Virus Diagnostic Testing: 30 Years ... - NIH
Mar 2, 2016 · Fourth- and fifth-generation HIV assays added p24 antigen detection to the screening assay, reducing the test-negative window to 11 to 14 days.
[23]
HIV Testing | HIV Partners - CDC
Jan 27, 2025 · Window period: An antigen/antibody test performed by a lab on blood from a vein can usually detect HIV infection 18 to 45 days after exposure.
[24]
Core Concepts - HIV Diagnostic Testing - Screening and Diagnosis
In 2014, the CDC and the Association of Public Health Laboratories (APHL) released an HIV diagnostic algorithm to allow for more accurate diagnosis of acute HIV ...
[25]
Transfusion Medicine History - AABB
1996 HIV p24 antigen testing of donated blood begins. Although the test does not completely close the HIV window, it shortens the window period.Missing: post- | Show results with:post-
[26]
Transfusion-Acquired HIV: History, Evolution of Screening Tests ...
Oct 8, 2022 · Prevention of HIV acquisition by blood transfusion from its emergence to the present day is reviewed, and current challenges are delineated.
[27]
Post-Exposure Prophylaxis (PEP) - HIV Prevention - HIVinfo - NIH
PEP refers to the use of HIV medicines to prevent HIV infection within 72 hours (3 days) after a possible exposure. PEP should be used only in emergency ...Missing: implications | Show results with:implications
[28]
Clinical Guidance for PrEP | HIV Nexus - CDC
Assess ongoing chances of HIV exposure and prescribe daily oral PrEP within 8 weeks after the last CAB injection or other prevention methods if HIV exposure is ...Key Points · Resources · Materials For You And Your...Missing: implications | Show results with:implications<|control11|><|separator|>
[29]
Consolidated guidelines on HIV prevention, testing, treatment ...
Jul 16, 2021 · These consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring bring together existing and new clinical and programmatic ...Missing: window period
[30]
[PDF] Methods for estimating HIV incidence - UNAIDS
This article provides a summary of current issues and recommended methods for estimating. HIV incidence, including cohort studies for direct measures of ...
[31]
Insight into treatment of HIV infection from viral dynamics models
65 days,7 reaching peak “viral loads” as high as 108 copies of viral RNA per mL of plasma (c/mL).8 Viral loads then decrease over the period of a few weeks to a ...
[32]
DIAGNOSTICS FOR HIV DIAGNOSIS - NCBI
The duration of the window period depends on three main factors: (1) the genetics of the virus, (2) the genetics and immunocompetence of the host and (3) what ...
[33]
Precise determination of time to reach viral load set point after acute ...
During the early phase of primary HIV-1 infection, plasma viral load increases sharply by several orders of magnitude to a peak in the first few weeks post- ...
[34]
Viral genetic variation accounts for a third of variability in HIV-1 set ...
The controlled time window of 6 to 24 months limits variability because of the stage of the infection for both the SPVL and GSVL measures. ... Henceforth, we use ...
[35]
A Case of Long-Term Seronegative Human Immunodeficiency Virus ...
In most instances, short-term seronegative HIV infection can been readily explained either by antibody-based testing during the short window period between HIV ...Abstract · Viral Testing · Results
[36]
Time to Seroconversion in HIV-Exposed Subjects Carrying ...
Here, we assessed time to seroconversion or duration of seronegative status in a group of 168 HIV exposed individuals, including 74 seroconverters and 94 HESN ...
[37]
Influence of HLA Class I Haplotypes on HIV-1 Seroconversion and ...
Jul 3, 2014 · Our study showed that the true effects of HLA class I haplotypes on HIV seroconversion and disease progression exist and the associations of HLA ...
[38]
HIV/ AIDS - National Centre for Infectious Diseases
Incubation Period The time from infection to development of detectable antibodies is generally 1- 3months. Between 1 and 6 weeks (median 3 weeks) after ...
[39]
HIV Testing Overview
The window period varies from person to person and also depends on the type of HIV test performed. Some tests can detect HIV sooner than others. (See image ...
[40]
Time Until Emergence of HIV Test Reactivity Following Infection With ...
Infections with virus other than HIV-1 subtype B may have different window periods with some of the tests evaluated. Variance estimates for the ITRIs were ...Missing: incubation | Show results with:incubation
[41]
What is the window period for HIV testing? - Aidsmap
May 11, 2024 · The window period refers to the time after infection and before seroconversion, during which markers of infection (p24 antigen and antibodies) are still absent.
[42]
WHO announces the development of guidelines on multiplex testing
Sep 10, 2025 · While the guideline will focus largely on application to HIV, viral hepatitis and STIs, it will provide critical principles for integration that ...
[43]
Rapid simultaneous self-testing of HIV and HCV viral loads with ...
Rapid simultaneous self-testing of HIV and HCV viral loads with integrated RNA extraction and multiplex RT-PCR in under 1 hour. August 2025; Biosensors and ...
[44]
Diagnosis and Management of Acute HIV Infection - HIVguidelines.org
Dec 11, 2024 · The mean time from exposure to onset of symptoms is generally 2 to 4 weeks, with a range of 5 to 29 days; however, some cases have presented ...
[45]
Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug ...
May 8, 2025 · To date, no human data are available to define a different window of time for nPEP initiation. CDC's oPEP guidelines include discussion of ...
[46]
A Timeline of HIV and AIDS
The HIV.gov Timeline reflects the history of the domestic HIV/AIDS epidemic from the first reported cases in 1981 to the present.
[47]
Prolonged seroconversion in an elite controller of HIV-1 infection
We describe a prolonged HIV-1 seroconversion in an elite controller (defined as having HIV-1 RNA persistently <50 copies/ml while untreated).
[48]
Serological tests for syphilis - PMC - NIH
Table 4. Window period of various serological tests. Serological test, Window period. FTA-Abs, 3rd week. VDRL, 2-6 weeks. TPHA, 4-5th week. Open in a new tab.
[49]
Syphilis - StatPearls - NCBI Bookshelf
The incubation period before the primary chancre manifestations is about 10 to 90 days, with a median of 21 to 25 days.[19][62][63] Even without treatment ...Missing: lag | Show results with:lag
[50]
Syphilis Serology - FPnotebook
Mar 1, 2025 · Primary Stage (Chancre stage). False Negatives are most common in the first 4 weeks; After one week: 30%; After three weeks: 90% · Secondary ...
[51]
Screening for Syphilis in Pregnancy - ACOG
Apr 4, 2024 · Screen all pregnant individuals serologically for syphilis at the first prenatal care visit, followed by universal rescreening during the third trimester and ...
[52]
[PDF] STI Screening Timetable - University Health Services
Window period (time from exposure until screening test turns positive). Incubation period (time between exposure and when symptoms appear). Chlamydia (urine ...<|control11|><|separator|>
[53]
Chlamydial Infections - STI Treatment Guidelines - CDC
Jul 22, 2021 · Test of cure (i.e., repeat testing after completion of therapy) to document chlamydial eradication, preferably by NAAT, at approximately 4 weeks ...Special Considerations · Ophthalmia Neonatorum Caused... · Infant Pneumonia Caused By C...
[54]
Herpes Testing - American Sexual Health Association
Jul 12, 2023 · Beyond 48 hours of the symptoms appearing, there is a risk of receiving a false negative test result.
[55]
HSV Tests for Genital Herpes: Test Types (PCR vs. Culture vs Blood)
Oct 30, 2024 · This test is best used within 48 hours of when you first see symptoms. After that time, the level of herpes virus starts to drop. That means ...